Systematic overview of cost–effectiveness thresholds in ten countries across four continents-Reference-Cited by-同舟云学术

Systematic overview of cost–effectiveness thresholds in ten countries across four continents

Published:2015-09 Issue:5 Volume:4 Page:485-504
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Schwarzer Ruth¹²,Rochau Ursula¹²,Saverno Kim¹³,Jahn Beate¹²,Bornschein Bernhard¹,Muehlberger Nikolai¹,Flatscher-Thoeni Magdalena⁴,Schnell-Inderst Petra¹²,Sroczynski Gaby¹²,Lackner Martina¹,Schall Imke¹,Hebborn Ansgar⁵,Pugner Karl⁶,Fehervary Andras⁷,Brixner Diana¹²³⁸,Siebert Uwe¹²⁹¹⁰

Affiliation:

1. Department of Public Health, Health Services Research & Health Technology Assessment, Institute of Public Health, Medical Decision Making & Health Technology Assessment, UMIT – University for Health Sciences, Medical Informatics & Technology, Eduard Wallnoefer Center I, 6060 Hall i.T., Austria

2. Division of Public Health Decision Modelling, Health Technology Assessment & Health Economics, ONCOTYROL – Center for Personalized Cancer Medicine, Innrain 66a, 6020 Innsbruck, Austria

3. Department of Pharmacotherapy, University of Utah, 30 South 2000, Salt Lake City, UT 84112, USA

4. Program on Health Policy, Administration, Economics & Law, Department of Public Health & Health Technology Assessment, UMIT – University for Health Sciences, Medical Informatics & Technology, Eduard Wallnoefer Center I, 6060 Hall i.T., Austria

5. F Hoffmann-La Roche AG, Market Access Policy, Grenzacher Str. 124, 4070 Basel, Switzerland

6. Amgen, Department of Health Economics & Reimbursement, Dammstrasse 23, 6301 Zug, Switzerland

7. Novartis International AG, Government Affairs Europe, Novartis Campus, Fabrikstrasse 1, 4002 Basel, Switzerland

8. Program in Personalized Health Care, Outcomes Research Center, Department of Pharmacotherapy, University of Utah, 30 South 2000, Salt Lake City, UT 84112, USA

9. Department of Health Policy & Management, Center for Health Decision Science, Harvard T.H. Chan School of Public Health, 718 Huntington Ave., Boston, MA 02115, USA

10. Institute for Technology Assessment & Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 101 Merrimac Street, Boston, MA 02114-4724, USA

Abstract

Aim: To provide an overview of thresholds for incremental cost–effectiveness ratios (ICERs) representing willingness-to-pay (WTP) across multiple countries and insights into exemptions pertaining to the ICER (e.g., cancer). To compare ICER thresholds to individual country's estimated ability-to-pay. Materials & methods: We included AHRQ/USA, BIQG-GOEG/Austria, CADTH/Canada, DAHTA@DIMDI/Germany, DECIT-CGATS/Brazil, HAS/France, HITAP/Thailand, IQWiG/Germany, LBI-HTA/Austria, MSAC/Australia, NICE/England/Wales and SBU/Sweden. ICER thresholds were derived from systematic literature/website search/expert surveys. WTP was compared with ATP using Spearman's rank correlation. Results: Two general and explicitly acknowledged thresholds (England/Wales, Thailand), implicit thresholds in six countries and different ICER thresholds/decision-making rules in oncology were identified. Correlation between WTP and ability-to-pay was moderate. Discussion: Our overview supports country-specific discussions on WTP and on how to define value(s) within societies.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer.15.38

Reference97 articles.

1. The Economics of Gene Therapy and of Pharmacogenetics

2. Gold M, Siegel J, Russell L, Weinstein M. Cost–effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).

3. Critical ratios and efficient allocation

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit;Critical Reviews in Oncology/Hematology;2024-10

2. Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck;Japanese Journal of Clinical Oncology;2024-08-29

3. Nirsevimab: Alleviating the burden of RSV morbidity in young children;Journal of Paediatrics and Child Health;2024-08-16

4. Cost-Utility of Venoarterial Extracorporeal Membrane Oxygenation in Refractory Cardiogenic Shock: A Brazilian Perspective Study;Arquivos Brasileiros de Cardiologia;2024-08

5. Custo-Efetividade da Oxigenação por Membrana Extracorpórea Venoarterial no Choque Cardiogênico Refratário: Um Estudo na Perspectiva Brasileira;Arquivos Brasileiros de Cardiologia;2024-08